AHL Partners’s bluebird bio BLUE Stock Holding History

AHL Partners’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-233	Closed	-$415K	–	1261
2017 Q3	$415K	Buy	+233	New	+$326K	0.01%	1095

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

AHL Partners's BLUE Position: Q4 2017 in Review

AHL Partners sold out of bluebird bio (BLUE) in Q4 2017, closing a stake of 233 shares — an estimated $415K sold.

AHL Partners first reported a position in BLUE in Q3 2017 and held it in 1 quarter. The position peaked at $415K in Q3 2017. 296 funds tracked by Wall St. Rank hold BLUE as of Q4 2017.

AHL Partners reported no remaining bluebird bio position as of Q4 2017 after selling out during the quarter.
AHL Partners sold 233 bluebird bio shares in Q4 2017, an estimated $415K.
AHL Partners first reported a position in bluebird bio in Q3 2017 and held it in 1 quarter.
AHL Partners's bluebird bio position peaked at $415K in Q3 2017.
296 funds tracked by Wall St. Rank held bluebird bio as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.